Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

4-Traders Homepage  >  Equities  >  Nasdaq  >  Pluristem Therapeutics       

PLURISTEM THERAPEUTICS
Mes dernières consult.
Most popular
  Report  
 SummaryChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
Financials ($)
Sales 2018 -
EBIT 2018 -35,7 M
Net income 2018 -36,7 M
Debt 2018 9,17 M
Yield 2018 -
Sales 2019 3,26 M
EBIT 2019 -37,8 M
Net income 2019 -38,5 M
Debt 2019 -
Yield 2019 -
P/E ratio 2018 -
P/E ratio 2019
Capi. / Sales2018 0
Capi. / Sales2019 45,1x
Capitalization 147 M
More Financials
Company
Pluristem Therapeutics, Inc. is a biotechnology company, which engages in the provision of cell therapy development.It develops placenta-based cell therapy product candidates for the treatment of multiple ischemic, inflammatory and hematologic conditions.The company focuses on cell therapies for... 
More about the company
Surperformance© ratings of Pluristem Therapeutics
Trading Rating : Investor Rating : -
More Ratings
Latest news on PLURISTEM THERAPEUTICS
02/07PLURISTEM THERAPEUTICS : Issues Letter to Shareholders- Q2 2018
PU
02/07Pluristem Issues Letter to Shareholders
GL
02/06PLURISTEM THERAPEUTICS : Management's Discussion and Analysis of Financial Condi..
AQ
01/13PLURISTEM THERAPEUTICS : Pluristems PLX Cells Significantly Inhibit Cancer Cell ..
AQ
01/12Pluristem’s PLX Cells Significantly Inhibit Cancer Cell Growth in Newly..
GL
01/10PLURISTEM THERAPEUTICS : FDA Clears Pluristems Expanded Access Program to Initia..
AQ
01/09PLURISTEM THERAPEUTICS INC : Completion of Acquisition or Disposition of Assets,..
AQ
01/09FDA Clears Pluristem’s Expanded Access Program to Initiate Treatments o..
GL
2017Pluristem Granted Manufacturer Authorization and Good Manufacturing Practice ..
GL
2017Pluristem to Present Data on PLX-R18 in Treatment of Acute Radiation Syndrome..
GL
More news
Sector news : Biotechnology & Medical Research - NEC
02/15French pharma group Ipsen sees more asset purchases, U.S. growth
RE
02/15Oxford BioMedica wins second $100 million gene therapy contract
RE
02/14Bristol-Myers to pay $1.85 billion in cancer deal with Nektar
RE
02/14BRISTOL MYERS SQUIBB : Nektar to Partner on Cancer Therapy
DJ
02/13Drug copies ready to take next bite out of Roche's cancer sales
RE
More sector news : Biotechnology & Medical Research - NEC
News from SeekingAlpha
01/13YOUR DAILY PHARMA SCOOP : Lipocine's Gloomy Future, Puma Labeling Change, Concer.. 
01/12Where To Next? Tigenix Investors Have New Stem Cell Options 
01/12PREMARKET GAINERS AS OF 9 : 05 am 
01/12Pluristem?s PLX cells significantly inhibit cancer cell growth in newly publi.. 
01/10Cleveland Biolabs' Delay Supports Competitor Advantage In Acute Radiation Syn.. 
Chart PLURISTEM THERAPEUTICS
Duration : Period :
Pluristem Therapeutics Technical Analysis Chart | 4-Traders
Income Statement Evolution
Consensus
 
Mean consensus OUTPERFORM
Number of Analysts 3
Average target price 3,83 $
Spread / Average Target 182%
EPS Revisions
Managers
NameTitle
Zami Aberman Chairman & Co-Chief Executive Officer
Yaky Yanay President, Co-Chief Executive Officer & Director
Erez Egozi Chief Financial Officer, Secretary & Treasurer
Mark S. Germain Director
Nachum Rosman Independent Director
Sector and Competitors
1st jan.Capitalization (M$)
PLURISTEM THERAPEUTICS7.25%147
CELLTRION, INC.--.--%36 110
IQVIA HOLDINGS INC6.93%21 125
LONZA GROUP-7.82%18 606
INCYTE CORPORATION-6.91%18 063
NEKTAR THERAPEUTICS40.66%13 227